May 23, 2018 – San Diego, Calif. — Access Scientific, LLC announced completion of an in vivo study demonstrating the superior anti-thrombotic (i.e., anti-clotting) property of its unique intravascular catheter material, ChronoFlex C® with BioGUARD™ technology.
The study found that ChronoFlex C with BioGUARD demonstrates thrombo-resistance where it matters most — on the surface of the blood vessel. No other catheter material has demonstrated this clinically important effect.
While other catheter manufacturers claim anti-thrombotic properties that reduce thrombus (clot) formation “on the surface of the catheter,” these anti-thrombotic claims cite in vivo or in vitro studies that show diminished thrombus formation solely on the surface of the catheter. This finding is often and mistakenly conflated with deep vein thrombosis (DVT) – a condition known to be associated with high-risk complications like bloodstream infection or blood clot embolization. There is no evidence that thrombo-resistance on the surface of the catheter has any effect on diminishing DVTs in actual patients.
Today’s announcement may serve to explain, at least in part, why Access Scientific’s POWERWAND™ catheters consistently demonstrate fewer DVTs and fewer total complications (including bloodstream infections) than other catheters used for similar purposes. “We now know it is not just the POWERWAND atraumatic insertion techniques that allow the vessel lining to remain clean and smooth,” said Steve Bierman MD, the company’s Chief Medical Officer. “It is also the catheter material, ChronoFlex C, and our patented BioGUARD processing, that makes POWERWAND anti-thrombotic both on the catheter surface and on the vessel wall.”
As hospitals continue to face the pressures of Value-Based Purchasing, novel products like POWERWAND offer solutions that both improve patient outcomes and reduce overall costs.
Access Scientific said that in the coming months it will reveal results of another completed study (pending publication). Combined with the current announcement of superior anti-thrombogenicity, this next study demonstrate the value of ChronoFlex C with BioGUARD as the ideal material for a wide variety of indwelling vascular catheters.
Customers often ask, Why does the POWERWAND™ have so many fewer complications than the other midlines and extended-dwell catheters we have tried? Flip that over and it sounds like: Why do other non-POWERWAND midlines have so many more complications (DVTs, leaking, phlebitis, etc.) than POWERWAND midlines?
The answer is really quite simple: Cut catheters appear to cause irritation to the vessel lining (i.e., the intima), which in turn causes complications. Watch this video which depicts the dangers of cut catheters quite well.
The POWERWAND is not a cut catheter; its tip is thermoformed into an atraumatic ZERO-EDGE™ transition. Beyond that, the POWERWAND guidewire has a soft, plastic domed tip. Atraumatic POWERWAND insertion leads to superior clinical outcomes.
But there is more. The other midlines are all made of polyurethane or a polyurethane blend. Those polyurethane midlines with published outcome data all have higher bloodstream infection rates than POWERWAND. Why? Because the POWERWAND is not polyurethane. It is made of a remarkable new polymer called ChronoFlex C®, which before becoming a POWERWAND, goes through our proprietary manufacturing process. The result: Over 20,000 catheter-days of peer-reviewed, published studies, from 5 different investigators and 6 different institutions, with ZERO bloodstream infections.
Atraumatic insertion + Thermoformed ChronoFlex C = The undisputed best-in-class, POWERWAND midline and extended-dwell catheter. There is method to the POWERWAND magic.
I often travel to hospitals all over the country and hear stories from clinicians who are frustrated by peripheral IVs that don’t last. Think about your own practice – how often does it happen that you are called to start a peripheral IV on a hard stick patient only to have to restart it the next day?
Did you know that the median dwell time for an ultrasound-guided PIV is only 26 hours? All the skill, time and effort you and your colleagues apply to the placement of these vital lines, unfortunately, results in an IV that lasts barely more than a day. Why? Because PIVs are simply too short (and too easily kinked) to function for any substantial time in the deeper veins of the arm and forearm.
Fortunately, there is a solution: The first true extended dwell catheter designed to extend the life of ultrasound guided peripheral IVs up to 29 days – The new POWERWAND™ EDC–3French, 6 cm (2.4 inches).
The new 3Fr, 6 cm POWERWAND is longer than a PIV, capable of power-injection up to 8 mL/sec, and is designed for the same reliable blood-drawability and extended dwell times as the POWERWAND midlines. Made of ChronoFlex™C, this new tool in your toolbox, is ideal for renal patients–and vein preservation, in general; ultrasound guided PIVs, patient’s requiring extended treatment but who do not need the hemodilution afforded by the POWERWAND midlines.
Please consider this next great innovation from Access Scientific–the POWERWAND 3Fr, 6cm Extended Dwell Catheter. Your patients will thank you.
Steve Bierman, MD
Chief Medical Officer